mTOR, metabolism, and the immune response in HPV-positive head and neck squamous cell cancer

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• Mammalian target of rapamycin (mTOR) activation is a common finding in head and neck squamous cell carcinoma (HNSCC).
• Human papillomavirus (HPV)-related HNSCC, a distinct subtype, also shows mTOR activation.
• While HPV-positive (HPV+) HNSCC generally has a better prognosis, treatment failures, recurrence, and death are increasing.

Purpose of the Study:

• To review the rationale for using mTOR inhibitors as an adjuvant therapy for HPV+ HNSCC.
• To explore the role of mTOR signaling in HPV+ HNSCC.
• To highlight the connections between mTOR signaling, metabolism, and immune response in HPV+ HNSCC.

Main Methods:

• Review of preclinical and clinical studies on mTOR activation and inhibition in HNSCC.
• Analysis of the molecular mechanisms underlying HPV-related HNSCC.
• Exploration of the interplay between mTOR signaling, cellular metabolism, and anti-tumor immunity.

Main Results:

• Preclinical studies support the therapeutic potential of mTOR inhibitors in HNSCC.
• Clinical studies are beginning to evaluate mTOR inhibitors, but few focus specifically on HPV-related disease.
• Increasing incidence of HPV-related cancers contributes to rising treatment failures and mortality.

Conclusions:

• Adjuvant mTOR inhibition is a promising strategy for HPV+ HNSCC treatment.
• Understanding the interplay of mTOR signaling, metabolism, and immunity is crucial for optimizing therapy.
• Further research focusing on HPV+ HNSCC is needed to improve patient outcomes.